Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: Therapeutic implications

Leukemia

Volumn 28, Issue 2, 2014, Pages 373-383

  Bjorklund, C C ^a   Baladandayuthapani, V ^a   Lin, H Y ^a   Jones, R J ^a   Kuiatse, I ^a   Wang, H ^a   Yang, J ^a   Shah, J J ^a   Thomas, S K ^a   Wang, M ^a   Weber, D M ^a   Orlowski, R Z ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

ATRA; CD44; drug resistance; lenalidomide

Indexed keywords

BETA CATENIN; HERMES ANTIGEN; HYALURONIC ACID BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; MONOCLONAL ANTIBODY; RETINOIC ACID; SILTUXIMAB; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL ADHESION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; HYALURONIC ACID; IMMUNOLOGIC FACTORS; MICE; MULTIPLE MYELOMA; PROTEIN BINDING; THALIDOMIDE; TRETINOIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893778565     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.174     Document Type: Article

References (52)

1. Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med 2011; 62: 249-264.
2. Quach H, Kalff A, Spencer A. Lenalidomide in multiple myeloma: current status and future potential. Am J Hematol 2012; 87: 1089-1095.
3. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011; 286: 11009-11020.
4. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999; 154: 515-523.
5. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev 2003; 4: 33-45.
6. Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett 2007; 252: 225-234.
7. Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets 2010; 10: 287-306.
8. Van Phuc P, Nhan PL, Nhung TH, Tam NT, Hoang NM, Tue VG et al. Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther 2011; 4: 71-78.
9. Ohwada C, Nakaseko C, Koizumi M, Takeuchi M, Ozawa S, Naito M et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur J Haematol 2008; 80: 245-250.
10. Masson D, Denis MG, Denis M, Blanchard D, Loirat MJ, Cassagnau E et al. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br J Cancer 1999; 80: 1995-2000.
11. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA et al. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 2012; 53: 50-56.
12. Krause DS, Spitzer TR, Stowell CP. The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma. Arch Pathol Lab Med 2010; 134: 1033-1038.
13. Dahl IM, Turesson I, Holmberg E, Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood 1999; 93: 4144-4148.
14. Vincent T, Mechti N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004; 18: 967-975.
15. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469-6478.
16. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481-490.
17. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011; 152: 579-592.
18. Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther 2008; 7: 521-529.
19. Lu J, Zhang F, Zhao D, Hong L, Min J, Zhang L et al. ATRA-inhibited proliferation in glioma cells is associated with subcellular redistribution of beta-catenin via up-regulation of Axin. J Neurooncol 2008; 87: 271-277.
20. Dillard AC, Lane MA. Retinol Increases beta-catenin-RXRalpha binding leading to the increased proteasomal degradation of beta-catenin and RXRalpha. Nutrition Cancer 2008; 60: 97-108.
21. Lim YC, Kang HJ, Kim YS, Choi EC. All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/beta-catenin pathway. Eur J Cancer 2012; 48: 3310-3318.
22. Liu J, Bi G, Wen P, Yang W, Ren X, Tang T et al. Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol 2007; 4: 59-63.
23. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
24. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
25. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010; 115: 1343-1350.
26. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
27. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
28. Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009; 27: 5713-5719.
29. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
30. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679-686.
31. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759-1769.
32. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.
33. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
34. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147-2152.
35. Wang SJ, Bourguignon LYW. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 2011; 178: 956-963.
36. Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009; 15: 7462-7468.
37. Toole BP, Slomiany MG. Hyaluronan CD44 and emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 2008; 11: 110-121.
38. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L et al. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-cd44 interactions with small hyaluronan oligosaccharides. Cancer Res 2009; 69: 4992-4998.
39. Niesvizky R, Siegel DS, Busquets X, Nichols G, Muindi J, Warrell Jr RP et al. Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Br J Haematol 1995; 89: 217-218.
40. Musto P, Sajeva MR, Sanpaolo G, D'Arena G, Scalzulli PR, Carotenuto M. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma. Haematologica 1997; 82: 354-356.
41. Koskela K, Pelliniemi TT, Pulkki K, Remes K. Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial. Leuk Lymphoma 2004; 45: 749-754.
42. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-1076.
43. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
44. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
45. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2012; 118: 4771-4779.
46. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
47. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119: 2764-2767.
48. Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012; 119: 2731-2737.
49. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
50. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153-3162.
51. Hertweck MK, Erdfelder F, Kreuzer KA. CD44 in hematological neoplasias. Ann Hematol 2011; 90: 493-508.
52. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2012; 278: 1429-1443.